Evidence map›Paper›PMID 38798896›Full record

ArticleOpen forum infectious diseases2024

Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Leonora Muehlberg, Thomas Pabst, Carlo Largiadèr, Yolanda Aebi, Michael Hayoz, Konrad Muehlethaler, Stefan Zimmerli, Cédric Hirzel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Leonora MuehlbergDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Thomas PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
Carlo LargiadèrDepartment of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Yolanda AebiDepartment of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Michael HayozDepartment of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Konrad MuehlethalerDepartment of Clinical Microbiology, Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Stefan ZimmerliDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Cédric HirzelDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID https://orcid.org/0000-0002-7870-912X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.

Indexed as

acute myeloid leukemiaintensive chemotherapymyelodysplastic syndromeposaconazole prophylaxis

Identifiers

PMID38798896
PMCPMC11127630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.